These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 25567119)

  • 21. Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults.
    Saito Y; Moi ML; Takeshita N; Lim CK; Shiba H; Hosono K; Saijo M; Kurane I; Takasaki T
    BMC Infect Dis; 2016 Oct; 16(1):578. PubMed ID: 27756212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children.
    Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Pancharoen C; Boaz M; Bouckenooghe A; Feroldi E
    Vaccine; 2016 Nov; 34(46):5664-5669. PubMed ID: 27686833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year After Primary Immunization in Healthy Children in the Republic of Korea.
    Kim DS; Jang GC; Cha SH; Choi SH; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Bang J; Naimi Z; Bouckenooghe A; Bosch-Castells V; Houillon G
    Pediatr Infect Dis J; 2016 Feb; 35(2):e60-4. PubMed ID: 26535878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine: advisory committee on immunization practices, 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 May; 60(20):661-3. PubMed ID: 21617632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses.
    Lobigs M; Pavy M; Hall RA; Lobigs P; Cooper P; Komiya T; Toriniwa H; Petrovsky N
    J Gen Virol; 2010 Jun; 91(Pt 6):1407-17. PubMed ID: 20130134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(®)) induced neutralizing antibody titers.
    Van Gessel Y; Klade CS; Putnak R; Formica A; Krasaesub S; Spruth M; Cena B; Tungtaeng A; Gettayacamin M; Dewasthaly S
    Vaccine; 2011 Aug; 29(35):5925-31. PubMed ID: 21723353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Partially neutralizing potency against emerging genotype I virus among children received formalin-inactivated Japanese encephalitis virus vaccine.
    Fan YC; Chen JM; Chiu HC; Chen YY; Lin JW; Shih CC; Chen CM; Chang CC; Chang GJ; Chiou SS
    PLoS Negl Trop Dis; 2012; 6(9):e1834. PubMed ID: 23029592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low Protective Efficacy of the Current Japanese Encephalitis Vaccine against the Emerging Genotype 5 Japanese Encephalitis Virus.
    Cao L; Fu S; Gao X; Li M; Cui S; Li X; Cao Y; Lei W; Lu Z; He Y; Wang H; Yan J; Gao GF; Liang G
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004686. PubMed ID: 27139722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-clinical and phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine.
    Kuzuhara S; Nakamura H; Hayashida K; Obata J; Abe M; Sonoda K; Nishiyama K; Sugawara K; Takeda K; Honda T; Matsui H; Shigaki T; Kino Y; Mizokami H; Tanaka M; Mizuno K; Ueda K
    Vaccine; 2003 Nov; 21(31):4519-26. PubMed ID: 14575762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009-2012.
    Rabe IB; Miller ER; Fischer M; Hills SL
    Vaccine; 2015 Jan; 33(5):708-12. PubMed ID: 25498208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity of single-dose Vero cell-derived Japanese encephalitis vaccine in Japanese adults.
    Takeshita N; Lim CK; Mizuno Y; Shimbo T; Kotaki A; Ujiie M; Hayakawa K; Kato Y; Kanagawa S; Kaku M; Takasaki T
    J Infect Chemother; 2014 Apr; 20(4):238-42. PubMed ID: 24485326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial.
    Koren MA; Lin L; Eckels KH; De La Barrera R; Dussupt V; Donofrio G; Sondergaard EL; Mills KT; Robb ML; Lee C; Adedeji O; Keiser PB; Curley JM; Copeland NK; Crowell TA; Hutter JN; Hamer MJ; Valencia-Ruiz A; Darden J; Peel S; Amare MF; Mebrahtu T; Costanzo M; Krebs SJ; Gromowski GD; Jarman RG; Thomas SJ; Michael NL; Modjarrad K
    Lancet Infect Dis; 2023 Oct; 23(10):1175-1185. PubMed ID: 37390836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current recommendations for the Japanese encephalitis vaccine.
    Chen HL; Chang JK; Tang RB
    J Chin Med Assoc; 2015 May; 78(5):271-5. PubMed ID: 25841620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of Vero Cell Culture-derived Japanese Encephalitis Vaccine in Pediatric and Young Hematopoietic Stem Cell Transplantation Recipients.
    Assawawiroonhakarn S; Apiwattanakul N; Pakakasama S; Hongeng S; Anurathapan U; Yoksan S; Klinmalai C; Sae-Chew P; Techasaensiri C
    Pediatr Infect Dis J; 2021 Mar; 40(3):264-268. PubMed ID: 33427799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and safety of a single dose of a live attenuated Japanese encephalitis chimeric virus vaccine in Vietnam: A single-arm, single-center study.
    Vu TD; Nguyen QD; Tran HTA; Bosch-Castells V; Zocchetti C; Houillon G
    Int J Infect Dis; 2018 Jan; 66():137-142. PubMed ID: 29081368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
    Nasveld PE; Marjason J; Bennett S; Aaskov J; Elliott S; McCarthy K; Kanesa-Thasan N; Feroldi E; Reid M
    Hum Vaccin; 2010 Nov; 6(11):906-14. PubMed ID: 20864814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Product review on the JE vaccine IXIARO.
    Firbas C; Jilma B
    Hum Vaccin Immunother; 2015; 11(2):411-20. PubMed ID: 25621812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and safety of the third booster dose of the inactivated Japanese encephalitis vaccine in Korean children: A prospective multicenter study.
    Kwak BO; Kwon YS; Hong YJ; Shin SH; Eun BW; Ahn YM; Kim HM; Kim NH; Kim DH
    Vaccine; 2021 Apr; 39(14):1929-1932. PubMed ID: 33712352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.